{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-21-005288","form_type":"8-K","ticker":"RKDA","cik":"0001469443","company_name":"Arcadia Biosciences, Inc.","filed_at":"2021-12-20T23:59:59+00:00","discovered_at":"2026-05-14T18:04:12.669538+00:00","generated_at":"2026-06-27T23:39:31.069446+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Arcadia Biosciences CEO Matt Plavan resigns, appoints Kevin Comcowich as interim CEO","bullets":["Matt Plavan resigned as CEO, President, and board member, effective Dec 31, 2021.","Kevin Comcowich appointed interim CEO effective Jan 1, 2022; will remain board chair.","Comcowich to receive $30,833/month; Plavan severance: $61,666 on Jan 1 & Feb 1, $143,278 on Mar 1, 2022.","Plavan's stock options fully vest Dec 31, 2021, exercisable until June 30, 2024.","Related party: Company leases land from Comcowich's entity for hemp; total lease payments $240,000."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-21-005288","json":"https://secwatch.observer/filing/0000950170-21-005288.json","markdown":"https://secwatch.observer/filing/0000950170-21-005288.md","text":"https://secwatch.observer/filing/0000950170-21-005288.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1469443/000095017021005288/0000950170-21-005288-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1469443/000095017021005288/rkda-20211214.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T23:39:31.069446+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"52dd16c786","claim":"Kevin Comcowich was appointed as Interim Chief Executive Officer at Arcadia Biosciences, Inc..","evidence_excerpt":"The Company has appointed Kevin Comcowich, the current chairman of the Arcadia Board of Directors, as the Company’s Interim Chief Executive Officer, effective January 1, 2022, as the board of directors finalizes its search for a permanent CEO.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1469443/000095017021005288/0000950170-21-005288-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Interim Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"f3060c1f43","claim":"Matt Plavan resigned as Chief Executive Officer, President at Arcadia Biosciences, Inc..","evidence_excerpt":"On December 14, 2021, Matt Plavan submitted his resignation from his positions as Chief Executive Officer, President and as a member of the Board of Directors (the “Board”) of Arcadia Biosciences, Inc. (the “Company” or \"Arcadia\"), effective December 31, 2021 (“Separation Date”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1469443/000095017021005288/0000950170-21-005288-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Executive Officer, President"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}